USA – GPB Scientific, Inc., a Vista, Calif. and Richmond, Va.-based developer of breakthrough technologies for therapeutic cell production and bioprocessing, raised $25.5m in funding.
The round was led by Vensana Capital alongside strategic investor Amgen Ventures with ongoing participation from existing investors. Led by Mike Grisham, CEO, GPB Scientific is a biomedical company advancing the Curate™ Cell Processing System, which utilizes its proprietary microfluidic deterministic lateral displacement technology in a closed system that has demonstrated the ability to deliver high yield and quality to process CAR-T, stem, and other cells with the throughput and scalability required for cell and gene therapies. The company intends to use the funds to drive the clinical assessment, GMP production, and commercialization of the system. 06/04/2020
